These 2 “Goodwill Stocks” Could Help More Than 366 Million People

What if there was a way to reap high returns in the market…while positively affecting the lives of millions of people?

Don’t get me wrong. I work for one of the top financial publishers in the country. And our job is to make our customers money.

That’s the bottom line.

#-ad_banner-#But is it possible to make money and make a difference? 

As investors, we place our money and our trust in companies. Shouldn’t we also have some pride or belief in what that business does? 

Warren Buffett has been saying for years that you should only buy “companies you understand.” I think you could also add “companies you respect.” 

During a recent interview with Forbes magazine, John Mackey, the co-founder and co-CEO of Whole Foods Market (Nasdaq: WFM), was asked how companies can make a profit and give back to the community. This was his reply:

“Businesses can do both by practicing conscious capitalism [and] always being grounded in its “credo”: That business is inherently good because it creates value, it is ethical because it is based on voluntary exchange, it is noble because it can elevate our existence, and it is heroic because it lifts people out of poverty and creates prosperity.”

With this powerful statement in mind, here are two “Goodwill Stocks” that could make you money and give you the good feeling that comes with helping others…

1. Trinity Biotech PLC (Nasdaq: TRIB)

When StreetAuthority Analyst Andy Obermueller recommended Trinity Biotech in his Game-Changing Stocks newsletter, this is what he had to say: 

“No one gets a report card that tells them exactly how long and precisely how well they’re going to live — unless they’re diabetic. 

A highly-specialized blood test I undergo every 90 days is able to pinpoint exactly how well my diabetes is under control and the precise degree to which I am at risk for complications such as blindness, kidney failure, amputation and other devastating consequences of poor control. Diabetic patients who consistently have strong results on this ONE test are able to avoid complications and have the same life expectancy as a non-diabetic.” 

This important test is for levels of glycated hemoglobin — a measure of average blood sugar during the preceding three months.

And Trinity Biotech, a $300 million medical device company in Bray, Ireland, which almost no one has heard about, is the leader in this field. Trinity introduced its diabetes-testing device, the “Premier Hb9210,” in the United States in late 2011. Trinity says it expects to sell 200 of the $25,000 devices in the current fiscal year

And that’s likely just the start. There were an estimated 366 million diabetics worldwide in 2011. During the next two decades, the global diabetes population is expected to grow nearly 50%, according to Denmark’s Novo Nordisk (NYSE: NVO), a pharmaceutical company that supplies more than half of the world’s insulin. 

By the year 2030, it is expected that about one in 15 people worldwide will suffer from diabetes, giving rise to huge demand for treatment and diagnostic products.

So what makes Trinity’s offering special?

The game-changing aspects of Trinity’s new Premier product line up like ducks in row. 

As Andy puts it: 

The (Premier) machine is far easier to use. It generates results faster. The tests provide more reliable readings that help doctors and patients fine-tune care.”

Moreover, existing diagnostic systems work well for some people, but they don’t account for the many differences in blood chemistries among genders, races and ages. Trinity’s device, by contrast, delivers highly accurate results for everyone.

That’s a welcome trait in a global market. In addition to Europe and the United States, Trinity sells the Premier in South America, Southeast Asia, Turkey and Taiwan. 

But the best may be yet to come…

During the company’s quarterly earnings conference call on Oct. 18, 2012, Trinity said that approval for the Premier system is likely in China in January. The country is projected to be a 100-machine-a-year driver as China continues its massive hospital-building boom.

Add it all up and what you get is a best-in-class product being sold into a rapidly-expanding market — a recipe for success if there ever was one.

2. Pfizer Inc. (NYSE: PFE)

Pfizer is the world’s largest pharmaceutical firm, with annual sales near $70 billion. 

And in 2011, Pfizer donated $3.1 billion to charity. This number includes cash and products, and was the largest charitable effort by a U.S. corporation.

The company has initiated several worldwide heath initiatives devoted to helping people, with a special focus on Africa.

The company’s Global Health Fellows Program is an international corporate volunteer program that places Pfizer employees in short-term assignments in key emerging markets. During these assignments, volunteers train and promote health-service and provide health-prevention techniques to people in need. 

Since 2004, the company has trained more than 6,500 health care workers in Africa, and provided care and treatment to more than 30,000 patients.

The company has also done extensive work in the treatment and prevention of malaria…

From Pfizer’s website:

About 3.3 billion people — half of the world’s population — are at risk of contracting malaria. Every year, this leads to about 250 million malaria cases and nearly 1 million deaths. One in five (20%) childhood deaths in Africa is caused by malaria — every 30 seconds an African child dies from this disease.

Pfizer has an existing portfolio of essential anti-malarials that it distributes from a facility in Dakar, Senegal. This facility has been making and distributing valuable medicine to Africans for 25 years.

Although shares of Pfizer have gained 21% in the past year, they still trade at a modest forward price-to-earnings (P/E) ratio of 10.5 compared to the current S&P 500’s average of 16. 

The shares yield a little more than 3% and the dividend is projected to rise in the first quarter of 2013. The company has increased its dividend payout every year since 2009. 

Risks to Consider: Pfizer, being the enormous and well-established company that it is, carries much less risk than Trinity Biotech. However, if Andy’s thesis plays out, Trinity could see huge gains in the future.

Action to Take –>  From a pure investing standpoint, I think Pfizer is a buy below $27. For more speculative investors, Trinity Biotech is a buy below $15.  

If you have any recommendations for “Goodwill Stocks” you would like to see us profile in the future, please feel free to contact me here.

P.S. — When you get in on the ground floor of a promising new trend or technology, the profits that can follow can change your life forever. Andy Obermueller’s Game-Changing Stocks is entirely devoted to finding the next big, life-changing investing idea. See his latest report for more ground-breaking investment plays.